Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.

The Journal of pediatrics - 1 Oct 2018

Stallings Virginia A, Sainath Nina, Oberle Megan, Bertolaso Chiara, Schall Joan I

Abstract excerpt

OBJECTIVE: To determine if ivacaftor treatment results in weight gain and improved pulmonary function in people with cystic fibrosis transmembrane conductance regulator gating mutations. STUDY DESIGN: Children and adults with cystic fibrosis and at least 1 cystic fibrosis transmembrane conductance regulator gating mutation were evaluated in this observational study before and after 3 months of ivacaftor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Chloride Channel Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Energy Metabolism

Share to Quality of Life

Share to Quinolones

Share to Weight Gain

Source

Identifiers

PMID: 30029855
DOI: 10.1016/j.jpeds.2018.05.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.PMID 30029855Read ↗

Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension.Semantic proximity Read ↗

Changes in nutrition and growth status in young children in the first 12 weeks of ivacaftor therapy.Semantic proximity Read ↗

Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation.Semantic proximity Read ↗

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.Semantic proximity Read ↗

Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.Semantic proximity Read ↗

Italian and North American dietary intake after ivacaftor treatment for Cystic Fibrosis Gating Mutations.Semantic proximity Read ↗

Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review.Semantic proximity Read ↗

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial.Semantic proximity Read ↗

Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor/tezacaftor/ivacaftor in adults with CF.Semantic proximity Read ↗

Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.Semantic proximity Read ↗

The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.Semantic proximity Read ↗

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal InflammationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.